NHI-2
NHI-2 is a lactate dehydrogenase A (LDHA) inhibitor with an IC50 of 14.7 µM. NHI-2 shows selective for LDHA over LDHB (IC50 = 55.8 µM) . NHI-2 is an efficient anti-glycolytic agent. NHI-2 enhances apoptosis, induces cell cycle arrest at S and G2 phases. NHI-2 has a broad spectrum anti-proliferative activity in cancer cells. NHI-2 affects extracellular acidification rate and ATP production. NHI-2 suppresses tumor growth in murine B78 melanoma tumor model[1][2].
Product Specifications
CAS Number
[1269802-97-2]
UNSPSC
12352005
Target
Apoptosis; Lactate Dehydrogenase
Type
Reference compound
Related Pathways
Apoptosis; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/nhi-2.html
Purity
99.10
Solubility
DMSO : 25 mg/mL (ultrasonic; warming)
Smiles
ON1C2=CC(C3=CC=CC=C3)=CC(C(F)(F)F)=C2C=C1C(OC)=O
Molecular Formula
C17H12F3NO3
Molecular Weight
335.28
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
LDHA; LDHB
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
ATG5 (ATG5 autophagy Related 5 Homolog (S. cerevisiae), APG5, APG5-LIKE, APG5L, ASP, hAPG5) (Biotin)
